{"log_id": 202333169502157092, "direction": 0, "words_result_num": 55, "words_result": [{"probability": {"variance": 0.052559, "average": 0.70408, "min": 0.356608}, "location": {"width": 119, "top": 65, "height": 23, "left": 354}, "words": "胆切肥厚"}, {"probability": {"variance": 7.1e-05, "average": 0.991227, "min": 0.982787}, "location": {"width": 75, "top": 100, "height": 47, "left": 194}, "words": "药有"}, {"probability": {"variance": 8.9e-05, "average": 0.99462, "min": 0.959312}, "location": {"width": 363, "top": 86, "height": 32, "left": 355}, "words": "非常常见:肝酶水平升高(AST、ALT、AP)"}, {"probability": {"variance": 0.026163, "average": 0.918372, "min": 0.578782}, "location": {"width": 275, "top": 121, "height": 39, "left": 263}, "words": "公皮肤及皮下组织病症"}, {"probability": {"variance": 3.4e-05, "average": 0.99747, "min": 0.980977}, "location": {"width": 184, "top": 159, "height": 28, "left": 352}, "words": "非常常见:皮肤毒性"}, {"probability": {"variance": 0.000109, "average": 0.996224, "min": 0.93657}, "location": {"width": 785, "top": 182, "height": 37, "left": 299}, "words": "80%以上的患者可能发生皮肤毒性,主要表现为痤疮样皮疹和/或较少出现的例如瘙"}, {"probability": {"variance": 0.003524, "average": 0.982826, "min": 0.635917}, "location": {"width": 774, "top": 212, "height": 36, "left": 309}, "words": "痒、皮肤干燥、皮肤脱屑、多毛症或者指甲异常(如甲床炎)。其中约15%的皮肤毒性反应"}, {"probability": {"variance": 4e-05, "average": 0.997573, "min": 0.962641}, "location": {"width": 774, "top": 240, "height": 38, "left": 309}, "words": "较为严重,包括个别皮肤坏死的病例。这些不良反应大多发生在治疗的前3周内。如按"}, {"probability": {"variance": 5.7e-05, "average": 0.996927, "min": 0.955496}, "location": {"width": 773, "top": 271, "height": 36, "left": 309}, "words": "照所推荐皮肤反应的剂量调整方案及治疗指南(见“注意事项”)进行处理,通常在中断"}, {"probability": {"variance": 0.000296, "average": 0.992513, "min": 0.918539}, "location": {"width": 771, "top": 300, "height": 37, "left": 309}, "words": "治疗后皮肤症状可以自行消退,并无后遗症发生。按照NCI-CTC,2级皮肤毒性反应为"}, {"probability": {"variance": 1.6e-05, "average": 0.997346, "min": 0.979398}, "location": {"width": 655, "top": 335, "height": 31, "left": 310}, "words": "不超过50%的体表面积出现皮疹,3级为大于等于50%的体表面积出现皮疹"}, {"probability": {"variance": 0.000894, "average": 0.985463, "min": 0.898763}, "location": {"width": 255, "top": 366, "height": 29, "left": 347}, "words": "发生率未知:皮损的重叠感染"}, {"probability": {"variance": 0.005542, "average": 0.975759, "min": 0.612403}, "location": {"width": 733, "top": 392, "height": 36, "left": 348}, "words": "西妥昔单抗导致的皮损可能引发患者的重叠感染(例如金黄色葡萄球菌)。这种重叠感"}, {"probability": {"variance": 0.001951, "average": 0.99016, "min": 0.716276}, "location": {"width": 772, "top": 422, "height": 36, "left": 308}, "words": "染会导致一些并发症,例如蜂窝织炎、丹毒、或潜在的致命性结果、葡萄球菌性烫伤样皮肤"}, {"probability": {"variance": 6e-06, "average": 0.998428, "min": 0.992396}, "location": {"width": 157, "top": 459, "height": 25, "left": 309}, "words": "综合征和败血症等"}, {"probability": {"variance": 0, "average": 0.999426, "min": 0.998213}, "location": {"width": 82, "top": 496, "height": 25, "left": 347}, "words": "输液反应"}, {"probability": {"variance": 2e-05, "average": 0.996863, "min": 0.984128}, "location": {"width": 731, "top": 515, "height": 36, "left": 346}, "words": "非常常见:轻度至中度的输液反应,包括发热、寒战、头晕、或者呼吸困难等症状,主"}, {"probability": {"variance": 3.1e-05, "average": 0.995822, "min": 0.9805}, "location": {"width": 191, "top": 551, "height": 28, "left": 307}, "words": "要发生在首次滴注期间"}, {"probability": {"variance": 0.0077, "average": 0.970796, "min": 0.647033}, "location": {"width": 296, "top": 577, "height": 30, "left": 345}, "words": "轻度至中度粘膜炎,可能导致鼻衄"}, {"probability": {"variance": 4e-06, "average": 0.998506, "min": 0.993914}, "location": {"width": 234, "top": 609, "height": 25, "left": 346}, "words": "常见:重度输液反应,疲乏"}, {"probability": {"variance": 6.9e-05, "average": 0.995674, "min": 0.95753}, "location": {"width": 730, "top": 624, "height": 43, "left": 346}, "words": "重度输液反应在极罕见的情况下会导致致命的结果般发生在首次滴注期间或者滴注"}, {"probability": {"variance": 0.000773, "average": 0.992122, "min": 0.825526}, "location": {"width": 771, "top": 660, "height": 36, "left": 306}, "words": "后1小时内,但也有可能发生在输液结束以后的几个小时或者后续的输液治疗中虽然潜在"}, {"probability": {"variance": 0.000301, "average": 0.994581, "min": 0.895897}, "location": {"width": 769, "top": 685, "height": 40, "left": 307}, "words": "的作用机制尚未确定,但其中的一些反应可能实际上就是过敏反应可能导致的的症状包括"}, {"probability": {"variance": 0.000774, "average": 0.989064, "min": 0.863133}, "location": {"width": 768, "top": 719, "height": 31, "left": 307}, "words": "支气管痉挛、荨麻疹、低血压、意识障碍或休克。在极少数情况下会出现心绞痛、心肌梗塞"}, {"probability": {"variance": 4e-06, "average": 0.998473, "min": 0.994748}, "location": {"width": 116, "top": 754, "height": 25, "left": 307}, "words": "或者心跳骤停"}, {"probability": {"variance": 8e-06, "average": 0.998257, "min": 0.988544}, "location": {"width": 384, "top": 778, "height": 30, "left": 347}, "words": "上述不良反应的临床处置,参见“注意事项”"}, {"probability": {"variance": 7e-06, "average": 0.99837, "min": 0.993756}, "location": {"width": 75, "top": 817, "height": 25, "left": 311}, "words": "【禁忌】"}, {"probability": {"variance": 0.000218, "average": 0.991928, "min": 0.939375}, "location": {"width": 582, "top": 839, "height": 32, "left": 346}, "words": "已知对西妥昔单抗有严重超敏反应(3级或4级)的患者禁用本品"}, {"probability": {"variance": 0.000143, "average": 0.995316, "min": 0.932747}, "location": {"width": 628, "top": 866, "height": 35, "left": 346}, "words": "在开始联合治疗前,应考虑伊立替康的有关禁忌,请参阅其使用说明书"}, {"probability": {"variance": 1e-06, "average": 0.998965, "min": 0.996938}, "location": {"width": 112, "top": 908, "height": 25, "left": 314}, "words": "【注意事项】"}, {"probability": {"variance": 0, "average": 0.999826, "min": 0.999645}, "location": {"width": 86, "top": 939, "height": 25, "left": 347}, "words": "输液反应"}, {"probability": {"variance": 0.000907, "average": 0.991598, "min": 0.81639}, "location": {"width": 724, "top": 957, "height": 37, "left": 348}, "words": "如病人出现轻中度输液相关反应,应减慢西妥昔单抗的滴注速率,建议在此后的所"}, {"probability": {"variance": 9.3e-05, "average": 0.99497, "min": 0.960636}, "location": {"width": 306, "top": 990, "height": 33, "left": 308}, "words": "有滴注过程均采用该调整后的速率"}, {"probability": {"variance": 0.0001, "average": 0.994492, "min": 0.944372}, "location": {"width": 724, "top": 1014, "height": 37, "left": 348}, "words": "有报道使用本品会发生严重的输液相关反应(参见“不良反应”),症状多发于初次"}, {"probability": {"variance": 3.1e-05, "average": 0.99703, "min": 0.9707}, "location": {"width": 761, "top": 1044, "height": 36, "left": 306}, "words": "滴注过程中或初次滴注结束1小时以内,也可能在结束后数小时发生,或者在以后的注"}, {"probability": {"variance": 0.000184, "average": 0.996697, "min": 0.915859}, "location": {"width": 765, "top": 1072, "height": 35, "left": 306}, "words": "射中发生建议医生告知患者这种反应延迟发生的可能性,并要求患者出现反应症状时"}, {"probability": {"variance": 0.002873, "average": 0.987919, "min": 0.665191}, "location": {"width": 764, "top": 1098, "height": 35, "left": 307}, "words": "立即联系医生。一旦发生严重的输液相关反应,应立即并永久停用本品,并进行紧急处"}, {"probability": {"variance": 0, "average": 0.999767, "min": 0.999767}, "location": {"width": 24, "top": 1137, "height": 23, "left": 307}, "words": "理"}, {"probability": {"variance": 5e-06, "average": 0.99792, "min": 0.992111}, "location": {"width": 465, "top": 1158, "height": 30, "left": 348}, "words": "建议体能状况低下或伴有心肺疾病的患者应特别注意"}, {"probability": {"variance": 0, "average": 0.999569, "min": 0.998706}, "location": {"width": 86, "top": 1192, "height": 25, "left": 347}, "words": "呼吸困难"}, {"probability": {"variance": 1.4e-05, "average": 0.997857, "min": 0.983104}, "location": {"width": 714, "top": 1212, "height": 34, "left": 348}, "words": "呼吸困难为输液相关反应的一部分,可能于给药当时发生,与本品的使用密切相关"}, {"probability": {"variance": 9.5e-05, "average": 0.996659, "min": 0.94267}, "location": {"width": 763, "top": 1241, "height": 34, "left": 307}, "words": "但如果在治疗数周后发生呼吸困难,则可能与患者本身所患疾病有关(参见“不良反"}, {"probability": {"variance": 4.8e-05, "average": 0.996424, "min": 0.969507}, "location": {"width": 762, "top": 1269, "height": 36, "left": 306}, "words": "应”)老年患者、体能状况低下和伴有心脏或肺部疾病的患者,可能存在更高的与呼吸"}, {"probability": {"variance": 0.000486, "average": 0.993958, "min": 0.862196}, "location": {"width": 762, "top": 1298, "height": 34, "left": 307}, "words": "困难相关的风险,这种风险可能更严重和/或持续时间更长。使用本品治疗过程中患者"}, {"probability": {"variance": 3.3e-05, "average": 0.997324, "min": 0.970604}, "location": {"width": 504, "top": 1329, "height": 33, "left": 306}, "words": "如发生呼吸困难,建议医生观察患者的肺部疾病进展情况"}, {"probability": {"variance": 9e-06, "average": 0.99594, "min": 0.992982}, "location": {"width": 64, "top": 1373, "height": 24, "left": 346}, "words": "肺毒性"}, {"probability": {"variance": 5.8e-05, "average": 0.995434, "min": 0.95581}, "location": {"width": 720, "top": 1394, "height": 30, "left": 350}, "words": "570例在临床试验中接受爱必妥治疗的患者中,有4例(<0.5%)患者发生了间质"}, {"probability": {"variance": 0.00717, "average": 0.978599, "min": 0.468662}, "location": {"width": 766, "top": 1422, "height": 36, "left": 305}, "words": "性肺病(ILD),其中1例患者死亡如果患者出现急性肺部症状或者肺部症状加重,则"}, {"probability": {"variance": 0.000267, "average": 0.994663, "min": 0.898836}, "location": {"width": 761, "top": 1451, "height": 36, "left": 306}, "words": "需要中断爱必妥的用药。如果确定为间质性肺病,则需要永久性停止爱必妥的使用,同"}, {"probability": {"variance": 1e-06, "average": 0.998223, "min": 0.996734}, "location": {"width": 245, "top": 1487, "height": 26, "left": 305}, "words": "时患者应当得到合适的治疗"}, {"probability": {"variance": 0, "average": 0.999642, "min": 0.999227}, "location": {"width": 84, "top": 1528, "height": 27, "left": 347}, "words": "皮肤毒性"}, {"probability": {"variance": 0.00407, "average": 0.982231, "min": 0.604175}, "location": {"width": 711, "top": 1550, "height": 35, "left": 346}, "words": "患者发生严重的(≥3级;美国国立癌症中心一常见毒性标准;NCI-CTC)皮肤反应"}, {"probability": {"variance": 0.000515, "average": 0.992506, "min": 0.881507}, "location": {"width": 760, "top": 1580, "height": 35, "left": 306}, "words": "必须中断西妥昔单抗的治疗。只有当反应缓解到2级,才能重新进行治疗(参见“不良"}, {"probability": {"variance": 7.3e-05, "average": 0.996337, "min": 0.962877}, "location": {"width": 542, "top": 1612, "height": 31, "left": 307}, "words": "反应”)。如严重的皮肤反应属首次发生,不须调整本品的剂量"}, {"probability": {"variance": 1e-05, "average": 0.998082, "min": 0.986786}, "location": {"width": 720, "top": 1642, "height": 28, "left": 346}, "words": "如严重的皮肤反应为第2次或第3次出现,必须再次中断使用本品。只有当反应缓"}], "language": -1}